MRX006

Dual cavity for triple therapy dry powder inhaler (DPI). MRX006 is based on the open-inhale-close principle. It is suitable as an AB-rated substitutable device for triple combination therapies.

It is designed to accommodate a combination formulation of 2 or more APIs, one of which may be chemically incompatible with the others, as with fluticasone, umeclidinium and vilanterol.

MRX006 offers unequalled technology tailored to current regulations and high-performance expectations.

Interested parties are invited to contact Merxin Ltd as soon as possible to secure access to a technology that will drive the next wave of inhaled finished dosage forms.